Cottonseed compound plus immunotherapy takes on tough colorectal cancer
NCT ID NCT07656766
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining sintilimab (an immunotherapy) with gossypol acetate (a compound from cottonseed) can shrink tumors in people with advanced colorectal cancer that has not responded to at least two prior treatments. The study will enroll 32 adults aged 18 to 75 with a specific tumor type (pMMR/MSS). Participants take gossypol daily for a lead-in period, then receive sintilimab infusions every three weeks. The main goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab (a cancer immunotherapy) and gossypol acetate (a cottonseed-derived compound)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced colorectal cancer that has not responded to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply widely. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat colorectal tumors?
- New drug combo aims to outperform standard therapy for advanced colorectal cancer
- New cocktail of drugs aims to tackle tough colorectal cancer
- New drug cocktail hopes to tackle advanced colon cancer
- New combo immunotherapy aims to shrink colon tumors before surgery
- Donor cells join fight against advanced cancers